Combination therapy of Juzentaihoto and mesenchymal stem cells attenuates liver damage and regresses fibrosis in mice

BACKGROUND: Liver cirrhosis is an end-stage multiple liver disease. Mesenchymal stem cells (MSCs) are an attractive cell source for reducing liver damage and regressing fibrosis; additional therapies accompanying MSCs can potentially enhance their therapeutic effects. Kampo medicines exhibit anti-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasawa, Takahiro, Nojiri, Shunsuke, Tsuchiya, Atsunori, Takeuchi, Suguru, Watanabe, Takayuki, Ogawa, Masahiro, Motegi, Satoko, Sato, Takeki, Kumagai, Masaru, Nakaya, Taiki, Ohbuchi, Katsuya, Nahata, Miwa, Fujitsuka, Naoki, Takamura, Masaaki, Terai, Shuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340055/
https://www.ncbi.nlm.nih.gov/pubmed/34409135
http://dx.doi.org/10.1016/j.reth.2021.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340055/
https://www.ncbi.nlm.nih.gov/pubmed/34409135
http://dx.doi.org/10.1016/j.reth.2021.07.002

Ejemplares similares